USPTO Examiner PAULSON SHEETAL R - Art Unit 3681

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18605638NEUROMODULATION WAVEFORM WATERMARKING AND PRESCRIBINGMarch 2024September 2024Allow620YesNo
18587367SYSTEM AND METHOD FOR IDENTIFYING TRANSDIAGNOSTIC FEATURES SHARED ACROSS MENTAL HEALTH DISORDERSFebruary 2024January 2026Abandon2210NoNo
18411959TRACKER MODULE FOR MONITORING THE USE OF A RESPIRATORY DEVICEJanuary 2024July 2025Allow1810NoNo
18528512SYSTEM AND METHOD FOR MOBILE MEDICATION TRACKINGDecember 2023December 2025Abandon2410NoNo
18514181METHODS AND SYSTEMS FOR SELECTING A MACHINE LEARNING ALGORITHMNovember 2023March 2025Allow1610NoNo
18500624ELECTROCARDIOGRAM-BASED GLOBAL DIAGNOSTIC SYSTEMS AND METHODSNovember 2023October 2025Abandon2310NoNo
18493544COMPUTER SYSTEM FOR CRISIS STATE DETECTION AND INTERVENTIONOctober 2023April 2025Allow1810NoNo
18461454COMPUTER-READABLE RECORDING MEDIUM STORING INFORMATION PROCESSING PROGRAM, METHOD FOR PROCESSING INFORMATION, AND INFORMATION PROCESSING APPARATUSSeptember 2023September 2025Abandon2510NoNo
18227425SYSTEM AND METHOD FOR AN ENHANCED HEALTHCARE PROFESSIONAL USER INTERFACE DISPLAYING MEASUREMENT INFORMATION FOR A PLURALITY OF USERSJuly 2023September 2024Allow1420YesNo
18220936SYSTEMS AND METHODS FOR IMPROVING INTERACTIONS OF INSURANCE PROVIDERS, PRESCRIBING HEALTHCARE PROFESSIONALS, AND MEMBERS ASSOCIATED WITH A HIGH VOLUME PHARMACYJuly 2023January 2026Abandon3020NoNo
18336938ELECTRONIC SYSTEMS AND METHODS FOR THE ASSESSMENT OF EMOTIONAL STATEJune 2023February 2025Allow2010NoNo
18184377SYSTEM AND METHOD FOR DETECTING, FORESTALLING AND TREATING CANCER PATIENTS USING ARTIFICIAL INTELLIGENCEMarch 2023May 2025Abandon2710NoNo
18024095SYSTEM AND METHOD FOR DIAGNOSING AND STAGING NEURODEGENERATIVE DISEASES ON THE BASIS OF THE SURFACE ROUGHNESS OF RETINAL LAYERSMarch 2023January 2026Abandon3520YesNo
18165756SYSTEM FOR REMOTE TREATMENT UTILIZING PRIVACY CONTROLSFebruary 2023May 2025Allow2810YesNo
18068223PREDICTING CHRONIC KIDNEY DISEASE PROGRESSIONDecember 2022February 2025Allow2610YesNo
17992652MULTI-PLATFORM PRESCRIPTION ROUTING SYSTEMNovember 2022February 2025Allow2740YesNo
17942393SYSTEM AND METHOD FOR PREDICTIVE RISK ASSESSMENT AND INTERVENTIONSeptember 2022April 2025Abandon3140YesNo
17817174SYSTEM AND METHOD FOR DECREASING TURNAROUND FOR PRE-AUTHORIZATIONS USING A SMART REQUEST FOR INFORMATION MODELAugust 2022August 2025Allow3620YesNo
17859608VIRTUAL MEDICAL ASSISTANT METHODS AND APPARATUSJuly 2022January 2025Allow3010YesNo
17757984PREDICTING AND ADDRESSING SEVERE DISEASE IN INDIVIDUALS WITH SEPSISJune 2022January 2026Abandon4330YesNo
17656963DECISION SUPPORT SYSTEM USING AN ARTIFICIAL INTELLIGENCE (AI) FRAMEWORK FOR SUGGESTING CODES FOR A CLINICAL RECORD FOR A PATIENT AND RELATED METHODS AND COMPUTER PROGRAM PRODUCTSMarch 2022April 2025Allow3620YesNo
17695635MEDICAL INFORMATION PROCESSING APPARATUS, AND MEDICAL INFORMATION LEARNING APPARATUSMarch 2022July 2025Allow4020YesNo
17693594SAFEGUARDS AGAINST USAGE OF INCORRECT PORTABLE MEDICINE DELIVERY DEVICESMarch 2022August 2025Allow4130YesNo
17310552SCHEDULE CALCULATION DEVICE, SCHEDULE MANAGEMENT SYSTEM, AND SCHEDULE CALCULATION METHODFebruary 2022March 2025Abandon4320NoNo
17581648SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR PREDICTIVE MAINTENANCEJanuary 2022September 2024Allow3240YesNo
17553037ANESTHESIOLOGICAL PROCEDURE RECORDING SYSTEM AND METHODDecember 2021May 2025Abandon4120NoNo
17545114Template and Method for Inputting and Disseminating Occupational and Physical Therapy InformationDecember 2021March 2025Abandon3920YesNo
17611733REMOTE HEALTH MONITORING SYSTEM AND METHOD FOR HOSPITALS AND CITIESNovember 2021November 2025Abandon4830NoNo
17524532METHOD FOR COMPREHENSIVE MANAGEMENT OF A HEALTH CONDITIONNovember 2021October 2024Abandon3520NoNo
17605848MEDICAL DEVICE AND METHOD FOR REMOTE-CONTROL OF A MEDICAL DEVICEOctober 2021April 2025Allow4240NoNo
17451463SYSTEM AND METHODS FOR EXAM SUGGESTIONS USING A CLUSTERED DATABASEOctober 2021November 2024Abandon3720NoNo
17501471SYSTEM AND METHOD FOR CONTACTLESS MONITORING AND EARLY PREDICTION OF A PERSONOctober 2021July 2025Allow4530YesYes
17497324AUTOMATED TRANSFORMATION DOCUMENTATION OF MEDICAL DATAOctober 2021March 2025Allow4130YesNo
17483847TWO-PHASED MEDICAL DIAGNOSISSeptember 2021February 2026Abandon5240YesYes
17447365HEALTHY BEHAVIOR SUPPORT DEVICE, METHOD, AND NON-TRANSITORY STORAGE MEDIUM STORING PROGRAMSeptember 2021August 2025Abandon4740YesNo
17402129System, Mobile Application and Process for an Advanced Recovery DeviceAugust 2021June 2025Abandon4640NoNo
17221736Validation of Health Status InformationApril 2021October 2024Abandon4330NoYes
17271473SYSTEM AND METHOD FOR REMOTELY OBTAINING DONOR INFORMATIONFebruary 2021February 2026Abandon5940NoNo
17178966PROCEDURE FOR THE GLOBAL UNIFIED REGISTRATION AND UNIVERSAL IDENTIFICATION OF DONORSFebruary 2021August 2024Allow4220NoNo
17056939MEDICAL ADHERENCE SYSTEM AND METHODNovember 2020April 2025Allow5320YesNo
17052661Treatment plan facilitatorNovember 2020October 2024Abandon4720YesNo
17075049SYSTEM FOR REMOTE TREATMENT UTILIZING PRIVACY CONTROLSOctober 2020November 2025Allow6051YesNo
16980136Systems and Methods for Neuro-Behavioral Relationships in Dimensional Geometric Embedding (N-Bridge)September 2020July 2024Allow4630NoNo
16995184SYSTEM AND METHOD FOR EFFICIENT EQUIPMENT RESOURCE ALLOCATIONAugust 2020December 2024Abandon5240NoNo
16912456CLINICAL ASSESSMENT TOOLJune 2020May 2025Abandon5960YesNo
16890477METHOD OF PREVENTING PHARMACEUTICAL FRAUD USING INTEGRATED IDENTITY MANAGEMENTJune 2020November 2024Abandon5340YesNo
16879176SYSTEM AND METHOD OF INTEGRATED UNIQUE IDENTITY MANAGEMENTMay 2020December 2024Abandon5550YesNo
16758729SYSTEM AND METHOD FOR ASSESSING PHYSIOLOGICAL STATEApril 2020February 2025Allow5850YesNo
16840227Automated Medical Diagnosis, Risk Management, and Decision Support Systems and MethodsApril 2020December 2024Abandon5660YesNo
16583652INFORMATION PROVISION METHOD, INFORMATION PROCESSING SYSTEM, INFORMATION TERMINAL, AND INFORMATION PROCESSING METHODSeptember 2019May 2025Abandon6040YesYes
16577817INFORMATION PROVISION METHOD, INFORMATION PROCESSING SYSTEM, INFORMATION TERMINAL, AND INFORMATION PROCESSING METHODSeptember 2019June 2025Abandon6030YesYes
16274874SYSTEM AND METHOD FOR PHYSICAL ACTIVITY INFORMED DRUG DOSINGFebruary 2019July 2025Allow60101YesNo
16324682PERSONALIZED NUTRITIONAL RECOMMENDATIONS USING BIOMARKER DATAFebruary 2019October 2025Abandon6050YesYes
16235093SYSTEMS AND METHODS FOR INTEGRATING A GLOBALLY SECURE COMMUNICATIONS NETWORK WITH STORED MEDICAL DIAGNOSTICSDecember 2018February 2025Allow6090YesYes
16159471HEALTHCARE FULFILLMENT METHODS AND SYSTEMSOctober 2018August 2024Allow6070YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PAULSON, SHEETAL R..

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
4
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
17.6%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
8
Allowed After Appeal Filing
1
(12.5%)
Not Allowed After Appeal Filing
7
(87.5%)
Filing Benefit Percentile
15.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 12.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PAULSON, SHEETAL R. - Prosecution Strategy Guide

Executive Summary

Examiner PAULSON, SHEETAL R. works in Art Unit 3681 and has examined 31 patent applications in our dataset. With an allowance rate of 35.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 52 months.

Allowance Patterns

Examiner PAULSON, SHEETAL R.'s allowance rate of 35.5% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PAULSON, SHEETAL R. receive 4.00 office actions before reaching final disposition. This places the examiner in the 97% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PAULSON, SHEETAL R. is 52 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +17.1% benefit to allowance rate for applications examined by PAULSON, SHEETAL R.. This interview benefit is in the 58% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 12.8% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 3% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 33.3% of appeals filed. This is in the 5% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 100% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 42% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.